Biosimilars – Forecast – Oncology
In 2024, sales of branded MAb biologics in oncology exceeded $48 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled $5.9 billion. Throughout the 2024-2034 forecast period, increasing numbers of branded biologics will lose patent protection, and biosimilars will enter the market and erode patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.
Table of contents
- Biosimilars - Forecast - Oncology
- Oncology MAb Forecasts
- G-CSF Forecasts
- Key takeaways
- Overview
- Drug-Specific Forecast Assumptions
Related Market Assessment Reports
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
